DavidTTeacheyMD

Pediatric Hematology & Oncology • Philadelphia, PA

Professor at Children's Hospital of Philadelphia and University of Pennsylvania Perelman School of Medicine

Join to view full profile

Dr. Teachey is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Teachey's full profile

Already have an account?

Office
3401 Civic Center Blvd
# Children
Philadelphia, PA 19104
Phone+1 215-590-3535

Fax+1 215-590-3992

Summary

Dr. David Teachey is a specialist in Pediatric Hematology & Oncology based in Philadelphia, PA. He completed his residency at Children's National Medical Center and further enhanced his skills at Children's Hospital of Philadelphia. With his extensive experience in lymphoblastic leukemia, lymphoma, and autoimmune diseases, he currently serves as a Professor at the Perelman School of Medicine and as an Attending Physician at the Children's Hospital of Philadelphia.

Education & Training

Children's Hospital of Philadelphia2005
Children's National HospitalResidency, Pediatrics, 1999 - 2002
Eastern Virginia Medical SchoolClass of 1999

Certifications & Licensure

FL State Medical License 2021 - Present
PA State Medical License 2002 - 2024
VA State Medical License 2021 - 2024
NY State Medical License 2021 - 2023
NC State Medical License 2020 - 2022
DC State Medical License 2001 - 2004
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Sirolimus for Autoimmune Disease of Blood Cells Start of enrollment: 2006 Dec 01
Completed
Phase 1, Phase 2
Tocilizumab and Hemophagocytic Lymphohistiocytosis (HLH) Start of enrollment: 2013 Dec 01
Withdrawn
Phase 2
Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma Start of enrollment: 2014 Oct 04
Active, not recruiting
Phase 3

Publications & Presentations

PubMed

492 citations
CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia
Shannon L. Maude, David T. Teachey, David L. Porter, Stephan A. Grupp
Blood. 2015-06-25
33 citations
Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy
Jochen Buechner, Stephan A. Grupp, Hidefumi Hiramatsu, David T. Teachey, Susana Rives
Blood Advances. 2021-01-26
33 citations
PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia.
Ingrid M. Ariës, Kimberly Bodaar, Salmaan Karim, Triona Ni Chonghaile, Laura Hinze
The Journal of Experimental Medicine. 2018-12-03

Journal Articles

Targeting EIF4E Signaling with Ribavirin in Infant Acute Lymphoblastic Leukemia
Nyla A Heerema, James W Davenport, Carolyn A Felix, Andrew J Carroll, ZoAnn E Dreyer, Alix E Seif, David T Teachey, Joanne M Hilden, Sarah K Tasian, Cheryl L Willman, ..., Nature

Press Mentions

Non-Coding DNA Found to Be Major Driver of T-lineage Acute Lymphoblastic LeukemiaAugust 15th, 2024
Dr. David Teachey Appointed Chair of Acute Lymphoblastic Leukemia Disease Committee in the Children’s Oncology GroupJuly 25th, 2024
MD-Researcher Keeps Her Eyes on the PrizeDecember 27th, 2022
Join now to see all

Grant Support

Targeting The Mtor Signaling Pathway In Autoimmune Lymphoproliferative SyndromeNational Institute Of Allergy And Infectious Diseases2011